alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Journals › The Lancet Neurology

Research published in The Lancet Neurology

Every study in the alzhub library that its record lists as published in The Lancet Neurology, summarised in plain English and scored out of 100.

These counts and lists are worked out from the library itself each time the page loads. A score rates how much weight a study can bear — its design, journal, evidence and recency — not whether its result is good news.

How the records spell this journal (4 spellings)

The 20 highest-scoring

  1. Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial The Lancet. Neurology · 2026-02-01 · · Peer-reviewed
  2. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial The Lancet. Neurology · 2021-07-01 · · Peer-reviewed
  3. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial The Lancet. Neurology · 2025-04-01 · · Peer-reviewed
  4. Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial The Lancet. Neurology · 2021-11-01 · · Peer-reviewed
  5. Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial The Lancet. Neurology · 2022-01-01 · · Peer-reviewed
  6. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis The Lancet. Neurology · 2016-04-08 · · Peer-reviewed

    This systematic review found that core CSF biomarkers and plasma total tau were strongly associated with Alzheimer's disease, while plasma Aβ42 and Aβ40 were not. It is about diagnosis, not treating, curing or preventing the disease.

  7. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis The Lancet. Neurology · 2009-09-24 · · Peer-reviewed

    This systematic review examined the prevalence and risk factors for dementia before and after stroke. It aimed to clarify conflicting data to help inform patients, carers, and service planning.

  8. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial The Lancet. Neurology · 2014-10-05 · · Peer-reviewed
  9. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 The Lancet. Neurology · 2018-11-26 · · Peer-reviewed

    This analysis estimated the global burden of dementia and found that a portion of it could be attributed to modifiable risk factors like high BMI, high fasting plasma glucose, smoking, and high intake of sugar-sweetened beverages. It highlights the potential for prevention by addressing these factors.

  10. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study The Lancet. Neurology · 2017-12-16 · · Peer-reviewed
  11. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts The Lancet. Neurology · 2020-05-01 · · Peer-reviewed

    This study, using data from four prospective cohorts, tested how well a blood measure of phosphorylated tau 181 (p-tau181) matched established spinal-fluid (CSF) and PET brain-scan markers of Alzheimer's disease, and whether it could be used in prediction models of change over time. Our record holds only the study's methods, not its results, so it cannot tell you how accurate the blood test was — check the original paper before drawing any conclusion. It evaluates a diagnostic test and does not test any treatment, cure or prevention.

  12. Frontotemporal dementia and its subtypes: a genome-wide association study The Lancet. Neurology · 2014-07-01 · · Peer-reviewed

    This genetic study found new gene regions linked to frontotemporal dementia, pointing to immune system processes and possibly lysosomal and autophagy pathways. The authors state these findings need to be replicated, so no treatment or prevention follows yet.

  13. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial The Lancet. Neurology · 2016-01-13 · · Peer-reviewed
  14. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials The Lancet. Neurology · 2007-09-01 · · Peer-reviewed
  15. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial The Lancet. Neurology · 2009-01-08 · · Peer-reviewed
  16. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial The Lancet. Neurology · 2016-12-10 · · Peer-reviewed
  17. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study The Lancet. Neurology · 2018-02-01 · · Peer-reviewed

    In people from families with inherited (autosomal dominant) Alzheimer's disease, brain scans of mutation carriers began to differ from those of non-carrier relatives in a set order: amyloid deposition first (on average 18.9 years before expected onset), then reduced glucose metabolism (14.1 years), then structural decline (4.7 years). These figures are averages across brain regions of when the differences became statistically detectable, not personal timelines, and they varied by several years. The study shows these changes come before the expected start of dementia in this inherited form; it does not show that one change causes the next, or that the same timing applies to late-life Alzheimer's.

  18. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease The Lancet. Neurology · 2005-11-01 · · Peer-reviewed

    Among 1,449 people aged 65–79 who were re-examined in 1998, an average of 21 years after a midlife survey, those who had done leisure-time physical activity at least twice a week in midlife had lower odds of dementia (odds ratio 0.48, 95% CI 0.25–0.91) and Alzheimer's disease (0.38, 0.17–0.85), after adjusting for factors including age, education, APOE genotype, vascular disorders, smoking and alcohol; the association was "more pronounced" in APOE ε4 carriers. This is an observational cohort, not a trial, so it shows an association rather than proof that exercise lowers risk; the authors conclude that regular activity "may reduce the risk or delay the onset" of dementia.

  19. Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis The Lancet Neurology · 2025-09-01 · · Peer-reviewed

    Across 113 studies, blood p-tau217 identified Alzheimer's pathology about 88% of the time and outperformed other tau variants like p-tau181. The authors warn that about 90% of the pooled studies had a high risk of bias from lack of predefined thresholds, so the reported accuracy may be inflated.

  20. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial The Lancet. Neurology · 2008-07-07 · · Peer-reviewed

    In this double-blind, placebo-controlled trial of 3,336 elderly people with high blood pressure (systolic 160–200 mm Hg), treatment lowered systolic pressure by 15 mm Hg more than placebo at 2 years, but the authors concluded it "does not statistically reduce incidence of dementia". Follow-up averaged only 2.2 years because the trial was stopped early, and the authors say the negative result "might have been due to the short follow-up… or the modest effect of treatment". They add that the findings, "when included in a meta-analysis, might support" blood-pressure treatment to reduce dementia.

See all 226 studies, with filters →

Newest additions

All 226, newest first →

From across this list

8 of the 226 studies in this list, picked by a fixed rule (a hash of each study's address), not by score or date. The same 8 appear here every time.

By review status

Other journals

The library by subject →